Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SH) Latest Company News

Oct 29, 2026, 10:18 UTC
Shanghai Pharmaceuticals reported third-quarter revenue of RMB 75.49 billion, up 2.7% year over year, and net profit of RMB 1.08 billion, up 57.15%.
Source:
- aastocks.com
Oct 29, 2026, 09:48 UTC
Shanghai Pharmaceuticals reported nine-month profit attributable to shareholders of RMB4.586 billion, down 10.9% year over year, and earnings per share of RMB1.24.
Source:
- aastocks.com
- aastocks.com
Oct 26, 2026, 02:23 UTC
Shanghai Pharmaceuticals and its subsidiary jointly established Ningbo Yongcheng Yiyao Pharmaceutical Co., Ltd., with registered capital of 540 million yuan.
Source:
- finance.sina.cn
Oct 23, 2026, 09:17 UTC
Shanghai Pharmaceuticals decided to terminate clinical trials and further development of its I025-A drug candidate, citing its assessment of future market value, business synergies and development costs.
Source:
- finance.sina.cn
Oct 9, 2026, 07:33 UTC
China’s National Medical Products Administration approved Shanghai First Biochemical Pharmaceutical Co., a subsidiary of Shanghai Pharmaceuticals, to manufacture clevidipine injectable emulsion in 50 ml:25 mg and 100 ml:50 mg strengths.
Source:
- finance.sina.cn
- aastocks.com
Sep 29, 2026, 12:43 UTC
Shanghai Pharmaceuticals announced it will sell its stake in Zeus Investment Limited, the vehicle that privatized Vitaco, to intended buyer DCP Capital in a deal with an enterprise value of US$397 million, with the transaction contract signed on 2026-09-29.
Source:
- finance.sina.cn
Sep 28, 2026, 08:02 UTC
Shanghai Pharmaceuticals announced that its subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical received a drug registration certificate from the National Medical Products Administration for isavuconazole sulfate for injection, approving production of the drug.
Source:
- finance.sina.cn
Sep 28, 2026, 08:02 UTC
Shanghai Pharmaceuticals' subsidiary Shanghai Jinhe Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for paclitaxel injection, approving production of the drug.
Source:
- finance.sina.cn
Sep 10, 2026, 10:48 UTC
Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.
Source:
- finance.sina.cn
Sep 7, 2026, 13:50 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.
Source:
- finance.sina.cn
Aug 27, 2026, 11:08 UTC
Shanghai Pharmaceuticals declared an interim dividend of RMB 0.10 per share for the six months ended June 2026, down from RMB 0.12 per share in the prior year.
Source:
- aastocks.com
Aug 27, 2026, 09:19 UTC
Shanghai Pharmaceuticals reported a net profit of 3.50 billion yuan for the first half of 2026.
Source:
Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.
Source:
- finance.sina.cn
Aug 24, 2026, 11:57 UTC
Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharma Holding will publicly list for transfer its 51% stake in subsidiary Shanghai Shangyao Xinte Dong'an Pharmacy Co., Ltd. via a property rights exchange, with a proposed minimum price of 179 million yuan.
Source:
- finance.sina.cn
- tmtpost.com
Aug 18, 2026, 00:17 UTC
Hangzhou Huqingyutang Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, started construction of a production workshop with an annual capacity of 2.2 billion capsules on August 15, 2026.
Source:
- finance.sina.cn
Jul 30, 2026, 07:51 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhonghua received product licenses from Health Canada for three Longhu products: classic and strong versions of cooling balm and Longhu rollerball essential balm.
Source:
- finance.sina.cn
Jul 24, 2026, 09:58 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. signed a limited partnership agreement to invest 300 million yuan as a limited partner in the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership.
Source:
Jul 20, 2026, 07:52 UTC
Shanghai Pharmaceuticals' subsidiary Shangyao Zhongyaosuo received a drug clinical trial approval notice from the National Medical Products Administration for Qingrun Yangmu Granules to treat dry eye.
Source:
- finance.sina.cn
Jul 17, 2026, 12:09 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. plans to list and transfer its 41% stake in subsidiary Shangyao Yiyi Pharmaceutical (Shanghai) Co., Ltd. via a public auction at a property rights exchange, with a base price of 330 million yuan.
Source:
- finance.sina.cn

601607.SH

Shanghai Pharmaceuticals reported third-quarter revenue of RMB 75.49 billion, up 2.7% year over year, and net profit of RMB 1.08 billion, up 57.15%.

Shanghai Pharmaceuticals reported nine-month profit attributable to shareholders of RMB4.586 billion, down 10.9% year over year, and earnings per share of RMB1.24.

Shanghai Pharmaceuticals and its subsidiary jointly established Ningbo Yongcheng Yiyao Pharmaceutical Co., Ltd., with registered capital of 540 million yuan.

Shanghai Pharmaceuticals decided to terminate clinical trials and further development of its I025-A drug candidate, citing its assessment of future market value, business synergies and development costs.

China’s National Medical Products Administration approved Shanghai First Biochemical Pharmaceutical Co., a subsidiary of Shanghai Pharmaceuticals, to manufacture clevidipine injectable emulsion in 50 ml:25 mg and 100 ml:50 mg strengths.

Shanghai Pharmaceuticals announced it will sell its stake in Zeus Investment Limited, the vehicle that privatized Vitaco, to intended buyer DCP Capital in a deal with an enterprise value of US$397 million, with the transaction contract signed on 2026-09-29.

Shanghai Pharmaceuticals announced that its subsidiary Shangyao Dongying (Jiangsu) Pharmaceutical received a drug registration certificate from the National Medical Products Administration for isavuconazole sulfate for injection, approving production of the drug.

Shanghai Pharmaceuticals' subsidiary Shanghai Jinhe Biopharmaceutical received a drug registration certificate from the National Medical Products Administration for paclitaxel injection, approving production of the drug.

Shanghai Pharmaceuticals announced that its subsidiary Shanghai Hefeng Pharmaceutical received the National Medical Products Administration's drug supplementary application approval notice, granting consistency evaluation for its lincomycin hydrochloride injection generic drug.

Shanghai Pharmaceuticals Holding Co., Ltd. signed a strategic cooperation framework agreement with the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences on September 7, 2026, to collaborate on innovative drug R&D and technology transfer.

Shanghai Pharmaceuticals declared an interim dividend of RMB 0.10 per share for the six months ended June 2026, down from RMB 0.12 per share in the prior year.

Shanghai Pharmaceuticals reported a net profit of 3.50 billion yuan for the first half of 2026.

Shanghai Pharmaceuticals' subsidiary Shanghai Hefeng Pharmaceutical received NMPA approval for promethazine hydrochloride injection to pass generic consistency evaluation.

Shanghai Pharmaceuticals announced that its wholly-owned subsidiary Shanghai Pharma Holding will publicly list for transfer its 51% stake in subsidiary Shanghai Shangyao Xinte Dong'an Pharmacy Co., Ltd. via a property rights exchange, with a proposed minimum price of 179 million yuan.

Hangzhou Huqingyutang Pharmaceutical Co., Ltd., a subsidiary of Shanghai Pharmaceuticals, started construction of a production workshop with an annual capacity of 2.2 billion capsules on August 15, 2026.

Shanghai Pharmaceuticals' subsidiary Shangyao Zhonghua received product licenses from Health Canada for three Longhu products: classic and strong versions of cooling balm and Longhu rollerball essential balm.

Shanghai Pharmaceuticals Holding Co., Ltd. signed a limited partnership agreement to invest 300 million yuan as a limited partner in the Shanghai Shangshi Biomedical Industry Private Equity Fund Partnership.

Shanghai Pharmaceuticals' subsidiary Shangyao Zhongyaosuo received a drug clinical trial approval notice from the National Medical Products Administration for Qingrun Yangmu Granules to treat dry eye.

Shanghai Pharmaceuticals Holding Co., Ltd. plans to list and transfer its 41% stake in subsidiary Shangyao Yiyi Pharmaceutical (Shanghai) Co., Ltd. via a public auction at a property rights exchange, with a base price of 330 million yuan.